Most MS researchers believe that it can, but there are few studies that confirm this impression.
More than 4,000 patients were followed for about 6 years, and those who were treated had lower disability scores than a natural history cohort. The reduction was 25% to 40% depending on the type of measurement. Improvement in quality of life measures showed an even greater difference of 40% to 45%. The lead author, Dr Jacqueline Palace, a neurologist at the University of Oxford in the UK, observed that if this effect is sustained over 20 years, treatment would be “cost-effective,” using a predefined target of about $50,000 per quality-adjusted life-year.
Dr. Jack Florin, MD
To schedule an appointment send us an email or call us at (714) 738-0800